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theBACKGROUND Left ventricular (LV) trabeculation is highly variable among individuals and is increased in some
diseases (e.g., congenital heart disease or cardiomyopathies), but its signiﬁcance in population-representative
individuals is unknown.
OBJECTIVES The goal of this study was to determine if excessive LV trabeculation in population-representative
individuals is associated with preceding changes in cardiac volumes and function.
METHODS For technical reasons, the extent of trabeculation, which is expressed as the ratio of noncompacted to
compacted (NC/C) myocardium, was measured on cardiac magnetic resonance (CMR) long-axis cine images in 2,742
participants in the MESA (Multi-Ethnic Study of Atherosclerosis) (mean age 68.7 years; 52.3% women; 56.4% with
hypertension; 16.8% with diabetes) at examination 5. These were considered in quintiles of trabeculation extent; the NC/
C ratio of quintile 5 was 2.46 to 5.41. We determined the relationship between the maximal NC/C ratio and the preceding
change (9.5 years between examinations 1 and 5) in end-systolic volume indexed (ESVi) to body surface area. Secondary
analyses assessed the associations between the maximal NC/C ratio and preceding changes in end-diastolic volume
indexed (EDVi) to body surface area and the ejection fraction (EF).
RESULTS Over 9.5 years, the ESVi decreased by 1.3 ml/m2, the EDVi decreased by 5.1 ml/m2, and the EF decreased
by 0.6% (p < 0.0001). Even in subjects with excessive trabeculation, there were no clinically relevant differences in
LV volumes and systolic function changes among the quintiles of trabeculation extent.
CONCLUSIONS Greater extent of, and even excessive, LV trabeculation measured in end-diastole in asymptomatic
population-representative individuals appeared benign and was not associated with deterioration in LV volumes or
function during an almost 10-year period. (J Am Coll Cardiol 2014;64:1971–80) © 2014 by the American College of
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ESVi = end-systolic
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LV = left ventricle/ventricular
LVEF = left ventricular
ejection fraction
LVNC = left ventricular
noncompaction
NC/C = noncompaction
to compaction
SSFP = steady-state
free precession
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1972H uman left ventricular (LV) cardiactrabeculation is highly variableamong individuals. Although some
differences may be related to ethnicity (1),
there have been concerns that extreme trabe-
culation may be either pathologic or a marker
of underlying heart muscle disease. LV non-
compaction (LVNC) is considered a distinct
form of cardiomyopathy (2,3) in which the
hallmark phenotypic feature is extensive LV
trabeculation. The diseasemay lead to cardiac
failure, thromboembolism, and malignant
arrhythmias. To date, only small studies
that used cardiovascular magnetic resonance
(CMR) imaging have described patterns and
the extent of LV trabeculation in cohorts with
a probable LVNC diagnosis on the basis of
symptoms, family history, or impaired cardiacfunction (4,5). However, although increased LV trabe-
culation is associated with other cardiac conditions,
such as cardiomyopathies (6) and congenital heart dis-
eases (7), it has also been frequently observed in
healthy individuals (8). Extensive LV trabeculation is
commonly detected following CMR imaging. When
LVNC imaging diagnostic criteria are met as an inci-
dental ﬁnding, a diagnosis of LVNC remains controver-
sial. The natural history and outcomes in people with
pronounced LV trabeculation in the absence of any
other structural heart abnormalities are unknown.SEE PAGE 1981This background combined with difﬁculties in
measuring trabeculae raise concerns that extensive
trabeculation in apparently normal individuals may
be a pre-phenotypic marker of underlying disease, a
marker of adverse outcome, or a normal phenotypic
variant. Accordingly, individuals with extensive tra-
beculation may be offered costly long-term follow-up
and are subject to the emotional and ﬁnancial impli-
cations of a cardiomyopathy diagnosis.
The purpose of this study was to determine the
relationship between the extent of LV trabeculationstitute for Health Research Cardiovascular Biomedical Research Unit
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Speciﬁcally, our primary aim was to evaluate whether
excessive LV trabeculation, which is measured as
the maximal ratio of noncompaction to compaction
(NC/C), was associated with preceding changes in the
end-systolic volume indexed (ESVi) to the body sur-
face area. In secondary analyses, we evaluated the
associations between the maximal NC/C ratio and
preceding changes in the end-diastolic volume in-
dexed (EDVi) to the body surface area and the
development of LV dysfunction, which was expressed
by deterioration in the LV ejection fraction (EF).
METHODS
STUDY POPULATION. The MESA (Multi-Ethnic Study
of Atherosclerosis) is a population-based prospective
cohort study [see the MESA website (9) for a full list
of participating MESA investigators]. Between 2000
and 2002, 5,004 of the 6,814 study participants, who
were free of clinically recognized cardiovascular dis-
ease and from 4 different ethnicities, underwent CMR
imaging at enrollment (examination 1) (10). Of these,
3,016 participants underwent CMR imaging be-
tween 2010 and 2011 (examination 5). Study partici-
pants were excluded due to insufﬁcient image quality
(n ¼ 241) and incomplete CMR datasets (n ¼ 33),
leaving 2,742 participants (Figure 1). Clinical data,
including the incidence of heart failure, atrial ﬁbril-
lation, myocardial infarction, stroke, and transient
ischemic attacks, were available for all participants.
MESA criteria for clinical events and follow-up pro-
cedures were previously described (11). The institu-
tional review boards of each of the 6 participating
ﬁeld sites in the United States approved the study,
and all participants provided written informed con-
sent at the time of enrollment into MESA.
MAGNETIC RESONANCE IMAGING. CMR examina-
tions were performed at 6 centers (Baltimore,
Winston-Salem, New York, Minneapolis, Los Angeles,
and Chicago) using either a Signa Excite (Generalat Barts. Prof. Petersen’s work is supported by awards
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FIGURE 1 Flow Diagram of Exclusion Process
Exclusion criteria of participants from MESA for this study.
CMR ¼ cardiovascular magnetic resonance.
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1973Electric Medical Systems, Waukesha, Wisconsin) or
Avanto/Espree (Siemens, Erlangen, Germany) 1.5-T
MR scanners for examinations 1 and 5. Planning of
the cardiac cine images for both examinations was
standardized to minimize variation among centers.
Cine images were obtained with a temporal resolution
of approximately 50 ms or less using a segmented
k-space and an electrocardiographically gated, fast
spoiled gradient-recalled echo pulse sequence during
MESA examination 1 (12). Retrospectively, electro-
cardiographically gated long- and short-axis cine
images were acquired using a steady-state free pre-
cession (SSFP) sequence at MESA examination 5 (13).
IMAGE EVALUATION. LV volumes and funct ion .
All MESA examinations 1 and 5 CMR images were
analyzed for LV volumes and function in a core lab-
oratory and analyzed at a single image analysis center
by readers blinded to clinical outcomes, as previously
described (13,14). Calibration between the 2 CMR
examinations was performed in 498 participants
who had both image sequences acquired at MESAexamination 5. The calibration group was selected to
be representative of all body sizes. Calibration was
performed for both technologist readers (by re-
reading 498 MESA examination 1 images) and pulse
sequences (same technologist reader, who analyzed
both pulse sequences using identical software). All
calibration curves were found to be linear and were
ﬁtted with ordinary regression methods.
For quality control purposes, all readers indepen-
dently analyzed every 10th consecutive CMR exami-
nation. The overall interobserver intraclass correlation
coefﬁcients for LV mass and LV end-diastolic volume
were 0.95 and 0.96, respectively, and technical errors
of measurement were 6.1% and 5.4%, respectively.
The interobserver agreements were similar to those
of the baseline study (12).
LV trabeculat ion . CMR examinations were evalu-
ated for the NC/C ratio using the post-processing
software tool, CVI42 (Circle Cardiovascular Imaging
Inc., Calgary, Alberta, Canada). The NC/C ratio could
only be determined for the MESA examination 5 CMR
data because the CMR sequence used at the MESA
examination 1 did not provide the level of detail and
contrast required. Although there are different ap-
proaches to assessing the extent of LV trabeculation
in both echocardiography and CMR, we restricted
our analysis to the NC/C ratio proposed by Petersen
et al. (4).
Horizontal and vertical long-axis cine SSFP images
were used for measuring the thickness of the com-
pacted myocardium and of the trabeculations at the
center of 8 LV regions: anterior; inferior; septal; and
lateral at the mid-ventricular and apical levels at end-
diastole, as previously described by Kawel et al. (8)
(Figure 2). The NC/C ratio was calculated for each
segment. Measurements were not performed at the
LV base, because trabeculations are not typically
observed in this region. In normal individuals, the
true apex is usually very thin, with prominent tra-
beculations; therefore, it was also excluded (4,14).
Compacted myocardium was deﬁned as a myocardial
layer of homogeneous moderate signal intensity on
SSFP images without inclusion of blood with a higher
signal intensity. Trabeculations were deﬁned as a
meshwork of the trabeculae carneae of moderate
signal intensity adjacent to the compacted myo-
cardium interspersed with blood of higher signal
intensity. Measurements of the thickness of the
compacted myocardium and of adjacent trabecula-
tions were obtained perpendicular to the compacted
myocardium. Fifty percent of the thickness of the
chemical shift artifact (appearing as a black line) on
the epicardial surface was included in the compact
myocardium. Papillary muscles that were clearly
FIGURE 2 Measurement of NC/C Ratios
Example of an end-diastolic, 4-chamber steady-state free
precession image of a participant with a very high maximal
noncompaction to compaction (NC/C) ratio (¼ 4.2) in the MESA
examination 5. Red arrows show measurements of the com-
pacted myocardium; yellow arrows represent measurements of
the noncompacted (trabeculated) layer.
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1974observed as compact tubular structures were not
included in the measurements. Short-axis views
and cine mode were used in addition to separate
papillary muscles from trabeculation. The orientation
of long-axis images was cross-referenced with short-
axis views, which allowed exclusion of off-axis im-
ages. Measurements of 60 randomly selected studies
were repeated by the ﬁrst reader and by a second
reader to quantify intra- and interobserver variability.
The NC/C ratio >2.3 was considered a current diag-
nostic criterion for LVNC (criterion used by Petersen
et al.) (4).
STATISTICAL ANALYSIS. Unless otherwise stated,
descriptive statistics for continuous variables areModels With Maximal NC/C Ratio, Demographic Data, CMR Data, and Cla
ome Variables
nge Between
nations 1 and 5)
Univariable Regression Model 1
Beta (95% CI) R2 Beta (95% CI)
iastolic volume
ex (ml/m2)
1.6* (0.9 to 2.3) 0.008 1.9* (1.2 to 2.6) 0
ystolic volume
ex (ml/m2)
0.3 (0.1 to 0.8) 0.0009 0.5† (0.1 to 0.9) 0
) 0.4 (0.1 to 0.8) 0.0009 0.3 (0.1 to 0.7) 0
linear regression analysis models for the changes in the end-diastolic volume index (EDVi
nt variables in models incorporating the maximal noncompaction to compaction (NC/C) ratio
nal risk factors as predictor variables. Model 1: adjusted for age, sex, and ethnicity. Mode
F (for change in EF). Model 3: adjusted for Model 2 parameters plus diabetes, smoking hist
.presented as mean and the SD, if normally distributed.
Categorical variables are presented as a percentage.
Differences between quintiles were evaluated by
analysis of variance with post-hoc Tukey tests for
continuous variables and with chi-square tests for
categorical variables.
Simple and multivariate linear regression models
were developed to examine the relationship of the
independent variables (the maximal NC/C ratio, the
NC/C ratio >2.3 in 1 segment, and the NC/C ratio
>2.3 in >1 segment) to functional, continuous
dependent variables related to heart failure, which
included changes in the LV volumes and EF between
examination 1 and examination 5. Covariates used
for multivariable regression models are listed in
Table 1.
All statistical analyses were performed using R
software version 3.0.1 (R Foundation for Statistical
Computing, Vienna, Austria) (15).
Intraclass correlation coefﬁcients were used to
evaluate intra- and interobserver agreement. In all
cases, statistical signiﬁcance was set at p < 0.05
(2-tailed).
RESULTS
DEMOGRAPHICS. Detailed demographic and CMR
data are presented in Table 2. The mean age of study
subjects at examination 5 was 68.7 years (52.3%
women). Ethnicity was self-reported as Caucasian or
white in 42.1%, Chinese American in 12.5%, African
American/black in 24.9%, and Hispanic in 20.5%.
Hypertension was present in 56.4% of participants.
At examination 5, 536 (19.5%) of the study subjects
were treated with angiotensin-converting enzyme
inhibitors, 248 (9.0%) with angiotensin II antagonists,
475 (17.3%) with beta-blockers, and 1,035 (37.7%)
subjects were treated with 1 or more of the previous
agents. Four hundred twenty-three participants
(15.5%) were being treated for diabetes, and 1,456ssic Risk Factors
Multivariable Regression
Model 2 Model 3
R2 Beta (95% CI) R2 Beta (95% CI) R2
.034 2.7* (2.1 to 3.3) 0.261 2.6* (2.0 to 3.3) 0.269
.026 1.0 (0.6 to 1.4) 0.195 1.0* (0.6 to 1.4) 0.200
.013 0.2 (0.6 to 0.2) 0.324 0.2 (0.6 to 0.1) 0.320
), end-systolic volume index (ESVi), and ejection fraction (EF) between MESA exami-
, demographic data, baseline cardiac magnetic resonance (CMR) parameters at MESA
l 2: adjusted for Model 1 parameters plus baseline EDVi (for change in EDVi), ESVi
ory, total cholesterol, systolic blood pressure, and BMI. *p <0.001; †p <0.05.
TABLE 2 Demographic and CMR Data at MESA Examination 5
All
(n ¼ 2,742)
Quintile 1
NC/C: 0–1.41
(n ¼ 549)
Quintile 2
NC/C: 1.42–1.71
(n ¼ 548)
Quintile 3
NC/C: 1.72–2.00
(n ¼ 548)
Quintile 4
2.01–2.45
(n ¼ 548)
Quintile 5
2.46–5.41
(n ¼ 549) p Value
Age, yrs 68.7  9.1 69.1  9.2 69.1  9.3 68.6  8.9 68.6  9.0 68.0  9.2 0.29
Women 1,435 (52.3) 266 (48.5) 286 (52.2) 261 (47.6) 304 (55.5) 318 (57.9) <0.01
Race
Caucasian 1,154 (42.1) 230 (41.9) 242 (44.2) 207 (37.8) 238 (43.4) 237 (43.2) 0.49
Chinese American 343 (12.5) 60 (10.9) 75 (13.7) 82 (15.0) 69 (12.6) 57 (10.4) 0.18
Black/African American 682 (24.9) 148 (27.0) 141 (25.7) 139 (25.4) 131 (23.9) 123 (22.4) 0.61
Hispanic 563 (20.5) 111 (20.2) 90 (16.4) 120 (21.9) 110 (20.1) 132 (24.0) 0.07
Body mass index, kg/m2 27.9  5.1 28.3  5.2 28.1  5.2 28.1  5.3 28.0  5.2 27.2  4.7 <0.01
Height, cm 165.7  9.8 166.0  9.8 165.5  9.5 165.7  10.1 165.7  10.0 165.5  9.7 0.91
Weight, kg 76.9  16.5 78.0  16.0 77.3  17.1 77.5  17.5 77.0  16.5 74.8  15.4 <0.05
Hypertension 1546 (56.4) 323 (58.8) 326 (59.5) 314 (57.3) 305 (55.8) 278 (50.6) <0.05
Systolic blood pressure, mm Hg 122.6  20.0 123.7  21.1 125.7  20.8 122.9  20.3 121.4  19.0 119.4  18.1 <0.0001
Diastolic blood pressure, mm Hg 68.3  9.9 69.0  9.8 69.0  10.4 68.8  9.8 67.6  9.7 67.0  9.7 <0.001
Diabetes by 2003 ADA (n ¼ 2,613)
Normal 1,702 (62.5) 337 (61.7) 319 (58.5) 329 (60.5) 341 (62.5) 376 (69.2) 0.24
Impaired fasting glucose 564 (20.7) 104 (19.0) 122 (22.4) 118 (21.7) 118 (21.6) 102 (18.8) 0.57
Untreated diabetes 35 (1.3) 8 (1.5) 7 (1.3) 8 (1.5) 5 (0.9) 7 (1.3) 0.93
Treated diabetes 423 (15.5) 97 (17.8) 97 (17.8) 89 (16.4) 82 (15.0) 58 (10.7) <0.05
Family history of a heart attack 1127 (43.5) 240 (46.2) 226 (44.1) 206 (39.9) 243 (46.6) 212 (40.8) 0.1
Coronary disease 96 (3.5) 27 (4.9) 14 (2.6) 15 (2.7) 19 (3.5) 21 (3.8) 0.21
Smoking
Never 1275 (46.7) 242 (44.2) 260 (47.7) 262 (48.1) 247 (45.2) 264 (48.4) 0.82
Former 1249 (45.7) 260 (47.4) 240 (44.0) 245 (45.0) 262 (47.9) 242 (44.3) 0.78
Current 207 (7.6) 46 (8.4) 45 (8.3) 38 (7.0) 38 (6.9) 40 (7.3) 0.84
Education
No school 9 (0.3) 3 (0.5) 0 (0.0) 0 (0.0) 3 (0.5) 3 (0.5) —
Grades 1–8 196 (7.2) 39 (7.1) 45 (8.2) 38 (7.0) 32 (5.9) 42 (7.7) 0.66
Grades 9–11 119 (4.3) 26 (4.7) 22 (4.0) 31 (5.7) 17 (3.1) 23 (4.2) 0.34
Completed high school 445 (16.3) 87 (15.8) 73 (13.4) 98 (17.9) 101 (18.5) 86 (15.7) 0.24
Some college but no degree 435 (15.9) 84 (15.3) 90 (16.5) 92 (16.8) 98 (17.9) 71 (12.9) 0.31
Technical school certiﬁcate 203 (7.4) 39 (7.1) 44 (8.1) 44 (8.1) 40 (7.3) 36 (6.6) 0.88
Associate degree 145 (5.3) 26 (4.7) 36 (6.6) 26 (4.8) 25 (4.6) 32 (5.8) 0.53
Bachelor’s degree 555 (20.3) 116 (21.1) 110 (21.1) 95 (17.4) 109 (19.9) 125 (22.8) 0.36
Graduate or professional school 630 (23.0) 129 (23.5) 126 (23.1) 122 (22.3) 122 (22.3) 131 (23.9) 0.97
LV end-diastolic volume index, ml/m2 65.2  13.6 62.4  14.3 63.5  13.4 65.7  13.1 66.0  13.3 68.3  13.2 <0.0001
LV end-systolic volume index, ml/m2 25.0  8.5 24.1  9.3 23.9  8.0 25.4  8.6 25.5  8.4 26.3  8.0 <0.0001
LVEF, % 62.0  7.3 62  7.4 62.8  7.3 61.7  7.8 61.7  6.8 61.9  7.0 0.1
LV mass index, g/m2 66.4  13.8 68.1  14.3 68.2  14.9 67.3  14.0 65.1  12.8 63.1  12.4 <0.0001
Values are mean  SD or n (%). Subjects with the highest trabeculation (quintile 5) had larger left ventricular volumes, end-diastolic mass index, and blood pressure values, and
lower incidence of treated diabetes, weight, and body mass index.
ADA ¼ American Diabetes Association; LV ¼ left ventricle; LVEF ¼ left ventricular ejection fraction; NC/C ¼ noncompaction to compaction ratio.
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1975(53.3%) were current or former smokers. Impaired
systolic function (EF <50%) was present in 111 (4.0%)
subjects at baseline examination 1, but they were
symptom-free, and there were no differences among
the quintiles of the maximal NC/C ratio (p ¼ 0.62).
Extent of LV trabeculat ion . The NC/C ratio was
calculated in 19,320 (88.1%) segments; 2,616 (11.9%)
segments were excluded because of insufﬁcient
contrast between the blood pool and the myocardium
to conﬁdently measure the NC/C ratios. The intraclass
correlation coefﬁcient was 0.83 (p < 0.0001) forintraobserver NC/C ratio measurements and 0.82
(p < 0.0001) for interobserver measurements. The
LVNC criterion (NC/C ratio >2.3) used by Petersen
et al. (4) was fulﬁlled in 706 (25.7%) participants for
at least 1 cardiac segment and in 218 (8.0%) partici-
pants for at least 2 segments.
The mean of the maximal NC/C ratio of each par-
ticipant’s analyzed segments was 1.96  0.66. This
was higher in women (2.0  0.68 vs. 1.92  0.64;
p < 0.001), but independent of age (p ¼ 0.051). There
were no differences in the maximal NC/C ratio among
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FIGURE 3 Changes in Cardiac Volumes and Function
Changes in left ventricular volumes and function between MESA examinations 1 and 5 and the relationship to the extent of LV trabeculation (in quintiles) at examinations
5 presented in 2 ways: the bottom panel shows box and whisker plots and the lack of clinically relevant changes in volume or function; the top panel shows similar
slopes for the quintiles of trabeculation extent with regard to volumes and function between both examinations. Boxes represent the interquartile range and whiskers
are within 1.5 times interquartile range. Outliers are plotted as points. The line within the box represents the median. *p <0.05; **p <0.01; ***p <0.001. NC/C ¼
noncompacted to compacted ratio. Exam ¼ examination.
TABLE 3 Cardiovascular Adverse Outcomes in Relation
to the Extent of LV Trabeculations
All Quintile 1 Quintile 2 Quintile 3 Quintile 4 Quintile 5
Atrial ﬁbrillation 24 10 (1.9) 7 (1.3) 1 (0.2) 3 (0.6) 3 (0.6)
Congestive heart failure 22 4 (0.7) 5 (0.9) 5 (0.9) 4 (0.7) 4 (0.7)
Stroke 28 4 (0.7) 8 (1.5) 10 (1.9) 2 (0.4) 4 (0.7)
Transient ischemic attack 17 4 (0.7) 3 (0.6) 4 (0.7) 4 (0.7) 2 (0.4)
Myocardial infarction 41 15 (2.8) 2 (0.4) 8 (1.5) 9 (1.7) 7 (1.3)
Hard cardiovascular endpoints 68 19 (3.6) 10 (1.9) 18 (3.4) 11 (2.0) 10 (1.9)
All cardiovascular endpoints 121 31 (6.0) 21 (4.0) 25 (4.8) 20 (3.8) 24 (4.6)
Values are n or n (%). The incidence of cardiovascular adverse outcomes in the whole studied cohort and quintiles
of maximal NC/C ratio are shown. Hard cardiovascular endpoints included myocardial infarction, resuscitated
cardiac arrest, and stroke. All cardiovascular endpoints include hard cardiovascular endpoints plus deﬁnite
angina, probable angina followed by coronary revascularization.
Abbreviations as in Table 2.
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1976the 4 ethnicities studied in MESA (1.98  0.69 in
Caucasians, 1.91  0.56 in Chinese Americans, 1.93 
0.66 in African Americans, and 2.00  0.65 in His-
panics; p ¼ 0.08).
The maximal NC/C ratio was correlated with the
number of segments that fulﬁlled the LVNC criteria
(r ¼ 0.76; p < 0.0001) and was greater in larger
LV cavities; the ratio increased by 0.2  2.1 for each
100-ml larger end-diastolic volume (p < 0.0001) and
by 0.3  3.6 for each 100-ml larger end-systolic
volume (p < 0.0001). There was no association of
the maximal NC/C ratio with the LVEF (p ¼ 0.16).
Relat ionsh ip between extent of t rabeculat ion
and precedent changes in LV volumes and EF.
We divided the cohort into quintiles by the extent of
Quintile 1
(0 to 1.41)
Quintile 2
(1.42 to 1.72)
Quintile 3
(1.73 to 2.01)
Quintile 4
(2.02 to 2.45)
Quintile 5
(2.46 to 5.41) p Value
–1.3 ± 8.0 –2.1 ± 7.1 –1.4 ± 7.5 –0.9 ± 7.4 –1.0 ± 7.2 0.08
–6.5 ± 13.1 –6.0 ± 12.4 –5.1 ± 12.1 –4.4 ± 12.3 –3.6 ± 11.3 <0.001
–1.4 ± 8.2 –0.1 ± 7.6 –0.4 ± 8.0 –0.8 ± 7.5 –0.3 ± 7.9 0.053
EXTENT OF NC/C RATIO
IN QUINTILES
CHANGE IN ESVI (ML/M2)
CHANGE IN EDVI (ML/M2)
CHANGE IN EF (%)
Zemrak, F., et al., J Am Coll Cardiol. 2014; 64(19):1971–80.
CENTRAL ILLUSTRATION Changes Over a 9.5-Year Period in the ESVi, EDVi, and EF
The changes over this time period in the end-systolic volume index (ESVi) and ejection fraction (EF) were not different among the quintiles of maximal noncompaction to
compaction ratio (NC/C), even in participants in whom the current “normal value” (<2.3) was exceeded. The decrease in the end-diastolic volume index (EDVi) was
smaller with an increasing extent of trabeculation; signiﬁcant differences were seen between quintiles 1 and 4 (p <0.05), between quintiles 1 and 5 (p <0.001), and
between quintiles 2 and 5 (p <0.01), but these changes were clinically insigniﬁcant.
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1977the maximal NC/C ratio. Detailed demographic data
and CMR parameters are presented in Table 2.
In the 9.5-year interval between examinations 1
and 5, the ESVi decreased, on average, by 1.3  7.3
ml/m2 (p < 0.0001), and there were no differences
among the quintiles of the maximal NC/C ratio
(Figure 3).
Similarly, the ESVi decreased, on average, by 5.1 
12.3 ml/m2 (p< 0.0001). The decrease was smaller with
an increasing extent of trabeculation; signiﬁcant dif-
ferences were seen between quintiles 1 and 4 (–6.5 
13.1 ml/m2 vs. –4.4  12.3 ml/m2; p < 0.05), between
quintiles 1 and 5 (–6.5 13.1ml/m2 vs. –3.6 11.3ml/m2;
p < 0.001), and also between quintiles 2 and 5 (–6.0 
12.4 ml/m2 vs. –4.4  12.3 ml/m2; p < 0.01) (Figure 3,
Central Illustration).
The EF decreased by 0.6%  7.8% (p < 0.0001) over
9.5 years; however, there were no differences among
the quintiles of the maximal NC/C ratio (Figure 3).
Several demographic parameters and clinical charac-
teristics differed by small amounts, but these reached
statistical signiﬁcance in univariate analyses with
regard to the extent or distribution among the quin-
tiles of the maximal NC/C ratio (Table 2).
After adjustment for age, sex, ethnicity, and base-
line CMR imaging parameters from examination 1
(Model 2), a 1-U greater maximal NC/C ratio (e.g., from
1 to 2, from 2 to 3, and so forth) was associated with
a 2.7  16.1 ml/m2 (p < 0.0001) decrease in the EDVi
and a 1.0  10.2 ml/m2 (p < 0.0001) decrease in the
ESVi. These models accounted for 26.1% and 19.5% ofthe variances in the volume changes, respectively
(Table 1). Multivariate regression models with con-
ventional risk factors (body mass index, systolic
blood pressure, diabetes, smoking, total cholesterol
to high-density lipoprotein ratio) (Table 1), as well as
exercise, education, and a family history of heart
attack showed similar ﬁndings to Model 2 (data not
presented). Overall, despite statistical signiﬁcance,
the observed changes in the EDVi and ESVi in rela-
tionship to the NC/C ratio were not clinically relevant.
The maximal NC/C ratio was not associated with a
change in the LVEF.
Sens i t iv i ty ana lys i s . The relationships described
earlier for the maximal NC/C ratio as a continuous
variable were repeated using the NC/C ratio >2.3 and
the number of segments with the NC/C ratio >2.3. All
results showed the same trends as for the continuous
NC/C ratio variable.
Extent of LV trabeculat ion and adverse c l in i ca l
events . The incidence of atrial ﬁbrillation, conges-
tive cardiac failure, stroke, transient ischemic attack,
history of myocardial infarction, composite cardio-
vascular endpoints, and all cardiovascular endpoints
in the quintiles of the maximal NC/C ratio are pre-
sented in Table 3. In view of the low-event incidence,
no formal statistical analysis was performed.
DISCUSSION
The long-term relationship between excess LV tra-
beculation and changes in myocardial function and
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1978structure was not previously known. This is the ﬁrst
study to show that a greater extent of LV trabecula-
tion was not associated with an absolute increase in
end-systolic and end-diastolic volumes during the
approximately 10 years of the MESA study. A greater
NC/C ratio was not associated with a decline in sys-
tolic function.
These results advance our understanding of ven-
tricular morphology in regard to “asymptomatic tra-
beculation” in relatively healthy individuals in the
community. In particular, MESA subjects with greater
trabeculation had only minor relative changes in left
ventricular end-diastolic volume index compared to
subjects with lesser trabeculation that, although sta-
tistically signiﬁcant, were unlikely to have clinical
implications.
PREVALENCE OF IMAGING DIAGNOSIS LVNC. The
estimated prevalence of LVNC is between 0.014% and
1.3% in the general population (2,16,17). However, all
echocardiographic or CMR-based imaging criteria for
LVNC were established on pre-selected, symptomatic
individuals with heart failure or cardiovascular com-
plications. It is important to emphasize that there are
currently no diagnostic tools, neither genetic nor
imaging, to identify patients affected by LVNC with
absolute certainty. This is the main reason cardiac
imaging studies have limitations when attempting
to determine diagnostic accuracies on the basis of
a likely LVNC diagnosis, rather than a deﬁnitive
diagnosis.
Recent studies that used high-resolution imaging
techniques, such as multidetector computed tomog-
raphy and CMR, revealed the frequent presence of
pronounced trabeculation that reached diagnostic
thresholds for LVNC in healthy volunteers (8,18).
This study, which extended the analysis by Kawel
et al. (8) of 323 MESA participants who were free
from cardiovascular disease to the whole MESA
cohort, showed that only 25.7% fulﬁlled the current
diagnostic criteria for LVNC, compared with the 43%
described by Kawel et al (8). This discrepancy is
likely to be partly related to software differences.
The CVI42 software used in this analysis allowed
identiﬁcation of “off-axis acquisitions,” whereas the
software used by Kawel et al. did not provide a cross-
reference tool.
ASSOCIATION OF EXTENT OF LV TRABECULATION
ON ADVERSE CARDIAC REMODELING AND CLINICAL
OUTCOMES. Baseline LV dimensions and the EF are
among the most powerful predictors of survival in
heart failure and in people without cardiovascular
disease, and are now well-established surrogate
markers in heart failure trials (19–22). In this study,
we evaluated the change in the ESVi, EDVi, and EF.Our main ﬁndings were that the maximal NC/C ratio
and other measures of the extent of LV trabeculation
were associated with small, but clinically negligible,
changes in LV parameters over the almost 10-year
MESA study period. The multivariate regression
model incorporating the maximal NC/C ratio, de-
mographic data, and the baseline CMR data (Model 2,
Table 1) increased the explained variance almost 10-
fold compared with the model that incorporated
only the extent of trabeculation and demographic
factors (Model 1, Table 1). This suggested that the
maximal NC/C ratio plays a very small clinical role in
cardiac remodeling. The EDVi and ESVi decreased
over the 9.5 years of the MESA study period, even in
participants with the most pronounced trabeculation
(by 3.6 ml/m2 and 1.0 ml/m2 in the highest quintile of
the maximal NC/C ratio).
In comparison, a previous study by Doughty et al.
in subjects with congestive heart failure due to
ischemic heart disease described an increase in the
EDVi by 10.5 ml/m2 over only 12 months in the pla-
cebo group (23).
Similarly, measures of the degree of LV trabecula-
tion were not associated with the adverse clinical
outcomes known to be associated with a clinical
diagnosis of LVNC. These data may seem contrary to
the many reports of embolic events in patients with
LVNC; however, the studied population was consid-
ered healthy, and the probability of LVNC (or other
cardiac diseases) was extremely low in this group.
IMPORTANCE OF CLINICAL INFORMATION WHEN
INTERPRETING IMAGING LVNC CRITERIA. Our study
again demonstrates that the criteria in Petersen et al.
(NC/C >2.3) are frequent ﬁndings in a “healthy”
population-representative cohort (24). Importantly,
our study underlines the importance of interpreting
such an imaging diagnosis in the context of the
available clinical information (24). Our ﬁndings sug-
gest that in subjects with a low pre-test probability for
cardiomyopathy or LVNC and marked trabeculation,
regular and frequent imaging and clinical follow-up
may be unnecessary.
The criteria in the Petersen et al. study were
derived from a group of patients with high pre-test
probability who were imaged at a tertiary cardiomy-
opathy center and showed high sensitivity and spec-
iﬁcity for diagnosing LVNC (4). Current diagnostic
criteria are applicable as a rule-in test if the suspicion
(pre-test probability) of LVNC is >10%; there criteria
could theoretically be used as a rule-out test if applied
in patients with low pre-test probability for LVNC (24).
STUDY LIMITATIONS. The data of the present study
must be interpreted in the context of the study
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: More
extensive LV trabeculation (the ratio of NC/C) did not
predict the development of clinically signiﬁcant LV
enlargement or systolic dysfunction over a decade of
follow-up.
TRANSLATIONAL OUTLOOK: Because adverse changes in
myocardial structure and function are an uncommon sequela of
LVNC, further studies in which large numbers of individuals are
followed for longer periods are needed to identify predictors
of phenotypic cardiomyopathy.
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1979design. As described in the Methods section, we were
only able to analyze trabeculation on the most recent
SSFP cine images from the MESA examination 5 data,
but could not analyze the gradient-recalled echo-
cardiogram cine images acquired during the MESA
examination 1. Although this makes the data more
applicable to current clinical practice, we implied
that trabeculation had not changed over the ap-
proximately 10 years beforehand. The rationale for
this implication is the evidence that the development
and extent of trabeculations were determined during
cardiac development in utero (25). Some case reports
describe an undulating phenotype of LV trabecula-
tions, but this is unlikely to be common enough to
inﬂuence the results of our study. Despite this, sur-
vivor bias may be present, and ﬁrm conclusions
on causality cannot be drawn. This question cannot
be addressed without this limitation for another
15 years, until MESA or other large-scale population-
based cohort studies, such as UK Biobank, have
sufﬁcient serial CMR studies using SSFP cines.
Adverse clinical events were rare and therefore
were not treated as primary outcomes in this study.
Measurement of the NC/C ratio is operator depen-
dent; however, there was a good intra- and inter-
observer agreement. We used only 1 approach to
measure the extent of LV trabeculations. Other re-
ported strategies differ with respect to measuring
the extent of LV trabeculations in short- or long-axis
views, measuring at end-diastole or end-systole,
calculating ratios based on the thicknesses of trabe-
culated and compacted myocardial layers or trabec-
ular mass as a percentage of total LV mass. There
is currently no consensus as to the best approach
because each has advantages and disadvantages with
respect to its reported diagnostic accuracy, repro-
ducibility, observer variability, and ability to avoid
inadvertent inclusion of papillary muscle in the
measurements.CONCLUSIONS
Although there is the potential for confounding and
survivor bias, this study did not ﬁnd a clinically rele-
vant impact of trabeculae on LV function measured
in end-diastole over an almost 10-year period in a
population of representative adult individuals.
This information should guide clinical decision
making in the common scenario of identifying pa-
tients with marked LV trabeculation and low pre-test
probability of LVNC, that there is no clear need for
follow-up imaging or pharmacotherapy in these
patients.
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